Research on low-molecular-weight PSMA (prostate-specific membrane antigen) inhibitors labeled with radioisotopes for the treatment of prostate cancer has generated significant interest in the fields of nuclear medicine and oncology. This evidence concerns the gene FOLH1 and prostate cancer.